Accelerated versus standard epirubicin followed by CMF versus capecitabine as adjuvant therapy of breast cancer: results of the randomised UK TACT2 trial (CRUK/05/19)

Thumbnail Image

Files

Accelerated versus standard epirubicin followed by...pdf (576.28 KB)

Embargo End Date

ICR Authors

Morden, James Peter
 Bliss, Judith
 Gillman, Alexa

Authors

Bliss, J
banerji, J
Gillman, A
Morden, J

Document Type

Journal Article

Date

Date Accepted

2017-05-10

Abstract

Citation

The Lancet Oncology

DOI

URI

https://repository.icr.ac.uk/handle/internal/710

Rights

https://creativecommons.org/licenses/by/4.0

Source Title

Publisher

ISSN

eISSN

Collections

Clinical Studies

Research Team

Clinical Trials & Statistics Unit
Clinical Trials & Statistics Unit

Notes